21:26 , Jul 27, 2018 |  BioCentury  |  Regulation

Biosimilar barriers

A coming showdown over anticompetitive contracting practices, coupled with an impending wave of patent expirations, could result in a wave of biosimilar approvals and launches in the U.S. over the next year, according to biosimilars...
14:50 , Apr 6, 2018 |  BC Week In Review  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
22:09 , Apr 5, 2018 |  BC Extra  |  Company News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

Samsung Bioepis Co. Ltd. and AbbVie Inc. (NYSE:ABBV) agreed to settle all litigation related to AbbVie's Humira adalimumab in a deal that will allow Samsung Bioepis to launch its biosimilar of the autoimmune drug, Imraldi...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
23:52 , Oct 6, 2017 |  BioCentury  |  Finance

Bargain shopping

With all companies valued over $1 billion increasing a median of at least 16.8% in 1H17, investors went bargain shopping in the $500-$999 million tier in 3Q17. The group outperformed all other market cap bands,...
21:43 , Sep 29, 2017 |  BC Week In Review  |  Company News

Amgen, AbbVie settle Humira biosimilar dispute

Amgen Inc. (NASDAQ:AMGN) has agreed to delay until early 2023 the U.S. launch of its biosimilar version of autoimmune drug Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in a deal announced Sept. 28 that resolves patent...
21:38 , Sep 29, 2017 |  BC Week In Review  |  Company News

Amgen, Simcere partner for biosimilars in China

Amgen Inc. (NASDAQ:AMGN) and Simcere Pharmaceutical Group (Nanjing, China) partnered to exclusively co-develop and commercialize biosimilars in China. The agreement includes four biosimilars from Amgen in inflammation and oncology, including ABP 501 and Mvasi bevacizumab-awwb...
00:11 , Sep 29, 2017 |  BC Extra  |  Company News

Amgen, AbbVie settle Humira biosimilar dispute

Amgen Inc. (NASDAQ:AMGN) has agreed to delay until early 2023 the U.S. launch of its biosimilar version of autoimmune drug Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in a deal announced Thursday that resolves patent litigation...
20:44 , Sep 27, 2017 |  BC Extra  |  Company News

Amgen, Simcere partner for biosimilars in China

Amgen Inc. (NASDAQ:AMGN) and Simcere Pharmaceutical Group (Nanjing, China) partnered to exclusively co-develop and commercialize biosimilars in China. The agreement includes four biosimilars from Amgen in inflammation and oncology, including ABP 501 and Mvasi bevacizumab-awwb...
15:18 , Sep 1, 2017 |  BC Week In Review  |  Clinical News

FDA approves Boehringer's biosimilar of Humira

Boehringer Ingelheim GmbH (Ingelheim, Germany) said FDA approved Cyltezo, a biosimilar of autoimmune drug Humira adalimumab from AbbVie Inc. (NASDAQ:ABBV). The biosimilar is indicated to treat rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriatic arthritis, ankylosing...